X

Trial Profile

Phase I/II study of the Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor BSI-201 in patients with newly diagnosed malignant glioma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iniparib (Primary) ; Temozolomide
Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
Focus Adverse reactions; Therapeutic Use
Sponsors Sanofi

Most Recent Events

07 Jul 2021 According to a TriAct Therapeutics media release, based on promising results from this study the company is designing a pivotal trial intended to support submission of an NDA in the U.S. and MAA in Europe.
12 Aug 2018 Results published in the Clinical Cancer Research.
10 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com